Research ArticleInfectious Disease

Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo

See allHide authors and affiliations

Science Translational Medicine  17 Feb 2016:
Vol. 8, Issue 326, pp. 326ra21
DOI: 10.1126/scitranslmed.aaf1061

Emerging therapeutics

The ability to treat emerging infections, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), has been limited by the turnaround time of developing new therapeutics. Now, Luke et al. report that transchromosomal bovines can rapidly produce large quantities of fully human polyclonal IgG antibodies to MERS-CoV after vaccination. These antibodies could neutralize MERS-CoV both in vitro and clear infection in mice in vivo. Human testing will confirm whether passive immunization with these antibodies can safely and effectively treat infection in infected individuals.

View Full Text

Stay Connected to Science Translational Medicine